LL-37

LL-37 (also known as Cathelicidin, CAP-18, hCAP-18) is a prominently researched experimental compound classified strictly within the Antimicrobial Peptide framework. Operating primarily through advanced pharmacological pathways, it functions by the only human cathelicidin antimicrobial peptide. LL-37 is a 37-amino acid cationic peptide that directly disrupts microbial membranes (bacteria, viruses, fungi) and neutralizes bacterial endotoxins (LPS). Beyond direct antimicrobial action, LL-37 modulates innate immunity by chemoattracting neutrophils, monocytes, and T-cells to infection sites. Promotes wound healing via EGFR-mediated keratinocyte migration and angiogenesis. Demonstrates potent anti-biofilm properties against resistant organisms. with a documented biological half-life of roughly 4 hours, in preclinical investigative trials and independent academic studies, researchers utilizing LL-37 have documented significant, quantifiable biological outcomes, primarily focusing on broad-spectrum antimicrobial, anti-biofilm, wound healing, immune modulation, anti-inflammatory. Typical research protocols investigate administering 100 to 100mcg via subq pathways 7x/wk. However, it is critically important to understand that while LL-37 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.